Evidence map›Paper›PMID 40735689›Full record

ArticlePNAS nexus2025

Modulation of immunoglobulin G oligomerization by variable domain glycans: A mechanism to regulate complement activation.

Roxane Biersteker, Leoni Abendstein, Sanne van de Bovenkamp, Hugo J van Dooren, Sebastiaan M W R Hamers, Joanneke C Kwekkeboom, Eva Maria Stork, Jan W Drijfhout, Theo Rispens, Carolien A M Koeleman and 5 more

Abstract read
In one paragraph

Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Roxane BierstekerDepartment of Rheumatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-3915-3472
Leoni AbendsteinDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0001-7634-5353
Sanne van de BovenkampDepartment of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Hugo J van DoorenDepartment of Rheumatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Sebastiaan M W R HamersDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-8535-1728
Joanneke C KwekkeboomDepartment of Rheumatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Eva Maria StorkDepartment of Rheumatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-9629-8950
Jan W DrijfhoutDepartment of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Theo RispensSanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, 1066 CX Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9600-1312
Carolien A M KoelemanCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-0814-4995
Leendert A TrouwDepartment of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0001-5186-2290
Thomas H SharpDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-1990-2333
René E M ToesDepartment of Rheumatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-9618-6414
Theresa KisselDepartment of Rheumatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-5749-8087

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin G (IgG) is a glycoprotein harboring conserved fragment crystallizable domain glycans, but it can also express variable domain glycans (VDGs). Elevated levels of VDGs are a hallmark of the autoantibodies most specific to rheumatoid arthritis and are also associated with other autoimmune diseases. Nonetheless, the effect of VDGs on IgG function remains poorly understood. This study investigates the impact of VDGs on the ability of antibodies to activate the complement system, a key immune effector mechanism. We demonstrate that VDGs on IgG inhibit the initiation of the classical complement pathway, as evidenced by complement activation assays with IgG displaying varying degrees of VDGs. Structure-function analyses show that VDGs reduce classical complement activation by impeding IgG oligomer formation on antigenic surfaces. As IgG oligomerization is essential for effective C1q binding, VDG-mediated interference with this process lowers IgG's complement activation potential. This impaired ability to recruit complement was further substantiated through direct visualization of IgG oligomer-C1q complexes on antigen-coated vesicles by cryoelectron tomography. Together, these data reveal that VDGs increase the functional diversity of IgG and identify a novel regulatory mechanism that modulates the ability of antibodies to activate one of their main immune effector mechanisms.

Indexed as

antibody effector mechanismsantibody structure–function relationshipcomplement activationrheumatoid arthritisvariable domain glycosylation

Identifiers

PMID40735689
PMCPMC12305304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.